BeiGene Announces Clinical and Preclinical Data to Be Presented at the 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting II
May 15, 2020 7:00 AM
Poster Presentations:
Title: | Preliminary safety and efficacy data of BGB-A333, an anti-PD-L1 monoclonal antibody, alone and in combination with tislelizumab in patients with advanced solid tumors |
Abstract #: | 9496 |
Poster Board #: | CT253 |
Session Category: | CT01 Phase 1 Adult Clinical Trial |
Session Title: | Phase 1 Trials in Progress |
Lead Author: |
Title: | BGB-10188, a highly selective PI3Kδ inhibitor with improved safety profile and superior anti-tumor activities in vivo |
Abstract #: | 664 |
Poster Board #: | 11 |
Session Category: | Experimental and Molecular Therapeutics |
Session Title: | PI3K/AKT/mTOR Inhibitors |
Lead Author: |
Title: | Preclinical characterization of BGB-11417, a potent and selective Bcl-2 inhibitor with superior antitumor activities in haematological tumor models |
Abstract #: | 3077 |
Poster Board #: | 11 |
Session Category: | Experimental and Molecular Therapeutics |
Session Title: | Topoisomerases, Tubulin, and Other Small Molecule Therapeutic Agents |
Lead Author: |
Title: | RAF dimer inhibitor lifirafenib enhances the antitumor activity of MEK inhibitor mirdametinib in RAS mutant tumors |
Abstract #: | 6415 |
Poster Board #: | 9 |
Session Category: | Experimental and Molecular Therapeutics |
Session Title: | Novel Therapeutic Approaches |
Lead Author: |
About
BeiGene Investor Contact | BeiGene Media Contact | |
+1 857-302-5189 ir@beigene.com | +1 857-302-5663 media@beigene.com |